Allarity Therapeutics announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20. The stock will begin trading on a split-adjusted basis when the market opens on April 9. “This strategic move aims to regain compliance with the Nasdaq’s minimum bid price requirement, alongside achieving other operational benefits,” the company said in a statement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
- Allarity Therapeutics Advances Precision Oncology with Stenoparib
- Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
- Allarity makes strategic pivot to focus solely on accelerating stenoparib
- Allarity Therapeutics Granted Extension for Nasdaq Compliance
